Intangible Assets

9 Months Ended

Sep. 30, 2020

Intangible Assets, Net (Excluding Goodwill) [Abstract]

INTANGIBLE ASSETS

The following table summarizes our intangible assets, net (in millions):


	September 30, 2020								December 31, 2019
	Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset - sofosbuvir	$	10,720	$	(4,777)	$	—	$	5,943	$	10,720	$	(4,253)	$	—	$	6,467
Intangible asset - axicabtagene ciloleucel	6,200		(1,019)		—		5,181		6,200		(761)		—		5,439
Other	1,203		(516)		(2)		685		1,098		(454)		(6)		638
Total finite-lived assets	18,123		(6,312)		(2)		11,809		18,018		(5,468)		(6)		12,544
Indefinite-lived assets - IPR&D	1,130		—		—		1,130		1,247		—		(5)		1,242
Total intangible assets	$	19,253	$	(6,312)	$	(2)	$	12,939	$	19,265	$	(5,468)	$	(11)	$	13,786

Aggregate amortization expense related to finite-lived intangible assets was $281 million and $844 million for the three and nine months ended September 30, 2020, respectively, $281 million and $868 million for the three and nine months ended September 30, 2019, respectively, and was primarily included in Cost of goods sold on our Condensed Consolidated Statements of Operations.

The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of September 30, 2020 (in millions):


Fiscal Year	Amount
2020 (remaining three months)	$	284
2021	1,137
2022	1,137
2023	1,137
2024	1,137
Thereafter	6,977
Total	$	11,809